Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURN-COVID Biobank
2024-515263-60-00Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of casirivimab + imdevimab, tixagevimab + cilgavimab, sotrovimab and Nirmatrelvir in coronavirus disease 2019 (COVID-19) (4 cohorts), sponsored by Amsterdam University Medical Center. Started Nov 2024; status: completed.
02
Drugs
casirivimab + imdevimabtixagevimab + cilgavimabsotrovimabNirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-515263-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515263-60-00.